|
|||||
|
|
Azacytidine plus olaparib for relapsed acute myeloid leukaemia,ineligible for intensive chemotherapy,diagnosed with a synchronous malignancy |
|
| Authors: | Sabina Iluta Sergiu Pasca Grigore Gafencu Ancuta Jurj Andreea Terec Patric Teodorescu Cristina Selicean Ciprian Jitaru Alexandra Preda Diana Cenariu Catalin Constantinescu Maria Iordache Bogdan Tigu Raluca Munteanu Richard Feder Delia Dima Mihnea Zdrenghea Diana Gulei Tudor-Eliade Ciuleanu Ciprian Tomuleasa |
| Affiliation: | 1. Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Cluj Napoca, Romania Department of Hematology, Ion Chiricuta Clinical Cancer Center Cluj Napoca, Cluj Napoca, Romania Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Cluj Napoca, Romania Contribution: Data curation (equal), Formal analysis (equal);2. Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Cluj Napoca, Romania Department of Hematology, Ion Chiricuta Clinical Cancer Center Cluj Napoca, Cluj Napoca, Romania Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Cluj Napoca, Romania Contribution: Investigation (equal);3. Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Cluj Napoca, Romania MRC Molecular Haematology Unit - The MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK Contribution: Formal analysis (equal);4. Research Center for Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Cluj Napoca, Romania Contribution: Formal analysis (equal);5. Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Cluj Napoca, Romania Contribution: Data curation (equal);6. Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Cluj Napoca, Romania Department of Hematology, Ion Chiricuta Clinical Cancer Center Cluj Napoca, Cluj Napoca, Romania Department of Leukemia, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, US Contribution: Investigation (equal);7. Department of Hematology, Ion Chiricuta Clinical Cancer Center Cluj Napoca, Cluj Napoca, Romania Contribution: Investigation (equal);8. Department of Hematology, Ion Chiricuta Clinical Cancer Center Cluj Napoca, Cluj Napoca, Romania Contribution: Data curation (equal);9. Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Cluj Napoca, Romania Department of Hematology, Ion Chiricuta Clinical Cancer Center Cluj Napoca, Cluj Napoca, Romania Contribution: Investigation (equal), Methodology (equal), Resources (equal);10. Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Cluj Napoca, Romania Contribution: Investigation (equal), Methodology (equal);11. Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Cluj Napoca, Romania Department of Hematology, Ion Chiricuta Clinical Cancer Center Cluj Napoca, Cluj Napoca, Romania Contribution: Investigation (equal), Methodology (equal);12. Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Cluj Napoca, Romania Contribution: Investigation (equal);13. Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Cluj Napoca, Romania Contribution: Formal analysis (equal);14. Department of Hematology, Ion Chiricuta Clinical Cancer Center Cluj Napoca, Cluj Napoca, Romania Contribution: Funding acquisition (equal);15. Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Cluj Napoca, Romania Department of Hematology, Ion Chiricuta Clinical Cancer Center Cluj Napoca, Cluj Napoca, Romania Contribution: Methodology (equal);16. Department of Hematology, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania Department of Medical Oncology, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Cluj Napoca, Romania Contribution: Investigation (equal);17. Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Cluj Napoca, Romania |
| Abstract: | |
| Keywords: | clinical scenario combination chemotherapy hypomethylating agents refractory acute myeloid leukaemia synthetic lethality |